LA
ALNY icon

Linden Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Linden Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,364
Closed -$6.55M – 473
2025
Q3 		$6.55M Buy
+14,364
New +$5.85M 0.04% 197

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Linden Advisors's ALNY Position: Q4 2025 in Review

Linden Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 14,364 shares — an estimated $6.55M sold.

Linden Advisors first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $6.55M in Q3 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Linden Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Linden Advisors sold 14,364 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $6.55M.
  • Linden Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Linden Advisors's Alnylam Pharmaceuticals position peaked at $6.55M in Q3 2025.
  • 851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Linden Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.